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Circulating RNAs in human body ﬂuids are promising candidates for diagnostic purposes.
However, the biological signiﬁcance of circulating RNAs remains elusive. Recently, small
non-coding RNAs, microRNAs (miRNAs), were isolated from multiple human body ﬂuids,
and these “circulating miRNAs” have been implicated as novel disease biomarkers.
Concurrently, miRNAs were also identiﬁed in the extracellular space associated with
extracellular vesicles (EVs), which are small membrane vesicles secreted from various
types of cells.The function of these secreted miRNAs has been revealed in several papers.
Circulating miRNAs have been experimentally found to be associated with EVs; however,
other types of extracellular miRNAs were also described. This review discusses studies
related to extracellular miRNAs, including circulating miRNAs and secreted miRNAs, to
highlight the importance of studying not only secretedmiRNAs, but also circulatingmiRNAs
to determine the contribution of extracellular miRNAs especially in cancer development.
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INTRODUCTION
Circulating RNAs have been isolated from human body ﬂuids
(Kamm and Smith, 1972; Fleischhacker and Schmidt, 2007).
Javillier and Fabrykant (1931) reported the ﬁrst discovery of cir-
culating nucleic acids in 1931, before Watson and Crick (1953)
reported the structure of DNA as a double helix. Furthermore,
Mandel andMetais (1947)permitted ribonucleic acid anddeoxyri-
bonucleic acid to be separately measured. Since then, many
researchers have attempted to use circulating RNA as disease
biomarkers; however, the origins andmeanings of circulatingRNA
are poorly understood.
MicroRNAs (miRNAs) are small non-coding RNAs that regu-
late multiple phenomena, including development, organogenesis,
and homeostasis (Ebert and Sharp, 2012). The mis-expression
of miRNAs results in the onset of diseases, such as immune
disease, cardiovascular disease, neurological disease, and cancer
(Mendell and Olson, 2012). In 2007, the Lötvall group demon-
strated that miRNAs were contained inside exosomes (Valadi et al.,
2007), which are small membranous vesicles derived from the
endosome (Raposo and Stoorvogel, 2013). Since the discovery
of miRNAs in exosomes, several reports conﬁrmed the existence
of miRNAs in apoptotic bodies (Zernecke et al., 2009), high-/
low-density lipoprotein (HDL/LDL; Vickers et al., 2011), and
RNA-binding proteins (Arroyo et al., 2011; Turchinovich et al.,
2011). Other studies have shown the existence of circulating
miRNAs in human serum, including the serum from pregnant
women (Chim et al., 2008) and cancer patients (Lawrie et al.,
2008). Researchers have identiﬁed placental-speciﬁc miRNAs in
the serum from pregnant women, which clearly disappeared after
childbirth, indicating that circulating miRNAs reﬂect the status
of the individual (Chim et al., 2008). Similarly, cancer-associated
miRNAs were higher in the serum from cancer patients than in
the serum from healthy individuals, indicating that circulating
miRNAs can be used as biomarkers to monitor the existence of
cancer cells in patients (Lawrie et al., 2008). These reports also
demonstrated the stability of circulating miRNAs in the blood,
despite the presence of large amounts of RNase (Reddi and Hol-
land, 1976). Since the discovery of miRNAs in blood, many
researchers have conﬁrmed the existence of miRNA in a variety
of other human body ﬂuids, such as serum, plasma, saliva, breast
milk, urine, and cerebrospinal ﬂuid, among others (Kosaka et al.,
2010a).
In this review, we chose miRNAs that were reported to have
functions in cell–cell communication and also reported to be a
potential biomarker, and we attempted to link the ﬁndings con-
cerning secreted miRNAs used in cell–cell communication tools
and circulating miRNAs used as biomarkers. This discussion may
increase broad interests and improve the current understanding of
the importance of extracellular miRNAs in cell–cell communica-
tion. We would like to discuss about the vesicles, such as exosomes,
microvesicles, and apoptotic bodies (Bobrie et al., 2011; Raposo
and Stoorvogel, 2013). The mean size of exosomes, 40–100 nm
in diameter, corresponds to that of the internal vesicles of mul-
tivesicular bodies from which they originate. Exosomes contain
enriched amounts of some speciﬁc markers, especially those of
endosomal origin including CD63, CD81, CD9, major histocom-
patibility complex class II, and so on. On the other hand, the
size of microvesicles varies between 50 nm and 1 μm in diame-
ter and the microvesicles are generated by budding at the plasma
membrane toward the outside of the cell. However, the term of
microvesicles has also been used for exosome-like vesicles and clear
distinction of exosome and microvesicles has not been established;
www.frontiersin.org September 2013 | Volume 4 | Article 173 | 1
“fgene-04-00173” — 2013/9/3 — 21:47 — page 2 — #2
Kosaka et al. Extracellular microRNA as a communication tool
therefore, we will use “extracellular vesicle (EV)” in this review,
according to the deﬁnition of the International Society for Extra-
cellularVesicles, when describing studies using ultracentrifugation
to isolate EVs.
miRNAs IN EXTRACELLULAR VESICLES OR NON-VESICLE
ASSOCIATED miRNAs
It has been shown that EVs, such as exosomes, microvesicles, and
apoptotic bodies, contain miRNAs with functions that have been
previously reported (Valadi et al., 2007; Zernecke et al., 2009).
The existence of non-vesicle associated miRNAs has also been
reported. These miRNAs bind to HDL/LDL (Vickers et al., 2011)
or RNA-binding proteins, such as Argonaute 2 (Ago2) (Arroyo
et al., 2011; Turchinovich et al., 2011) andAgo1 (Turchinovich and
Burwinkel, 2012). Interestingly, Arroyo et al. (2011) reported that
circulating miRNAs in plasma are predominantly coupled with
Ago2. The liver-speciﬁc miRNA, miR-122 has been detected only
in protein-associated fractions, suggesting that hepatocytes might
release miR-122 through a protein carrier pathway. In addition,
Turchinovich and Burwinkel (2012) showed that not only Ago2
but alsoAgo1-bound miRNAs has been identiﬁed in human blood
plasma. Intriguingly, they also found that some miRNAs in the
plasma did not derive from blood cells under normal conditions.
Although the abundance of miRNAs associatedwith RNA-binding
proteins has been recognized, the functions of these miRNAs in
cell–cell communications have not been clariﬁed.
miR-210
miR-210 is a hypoxia-inducible miRNA that is activated by the
master regulator of hypoxic stress, hypoxia-inducible factor (HIF)-
1alpha in a variety of cell types (Chan et al., 2012). This miRNA
has been implicated in erythropoiesis (Kosaka et al., 2008), iron
homeostasis (Yoshioka et al., 2012), angiogenesis (Fasanaro et al.,
2008), and cancer (Huang et al., 2009), which are also conditions
associated with hypoxic stress. This miRNA has also been impli-
cated in the regulation of DNA repair pathways (Crosby et al.,
2009). The function of miR-210 has been investigated, although
its exact contribution to the cancer microenvironment has not
been determined.
Recently, we observed that EVs isolated from metastatic breast
cancer cells promote metastasis via the induction of angiogene-
sis in the tumor (Kosaka et al., 2013). We also showed that EVs
contain multiple angiogenic miRNAs, and one of them, miR-
210, is responsible for angiogenesis. Indeed, the addition of
miR-210-enriched EVs induced the activation of endothelial cells
in vitro (Kosaka et al., 2013). Moreover, miR-210 expression is
known to be inversely correlated with a disease-free and overall
survival in breast cancer (Camps et al., 2008). Intriguingly, circu-
lating miR-210 in breast cancer patients has been reported. The
expression of circulating miR-210 is signiﬁcantly higher in plasma
from circulating tumor cell (CTC)-positive metastatic breast can-
cer patients compared with that in plasma from CTC-negative
metastatic breast cancer patients and controls (Madhavan et al.,
2012). The use of CTC as a prognostic marker in metastatic breast
cancer has been well documented (Lianidou and Markou, 2011);
however, adequate detection methods are still needed. Thus, cir-
culating miRNAs could be used to predict the status of patients
with metastatic breast cancer instead of detecting CTC. Moreover,
the indication of CTC is associated with bad prognosis for can-
cer patients, and circulating miR-210 might contribute to this
phenomenon (Madhavan et al., 2012).
Interestingly, circulating miR-210 levels were signiﬁcantly
higher in individuals with residual disease than in those who
achieved a pathologically complete response to trastuzumab (Jung
et al., 2012), administered at baseline before patients received
neoadjuvant chemotherapy, as a part of the standard treatment for
patients with human epidermal growth factor receptor 2 (HER-
2)-positive breast cancer. Indeed, circulating miR-210 was derived
from tumor cells, as reduced levels of circulating miR-210 were
observed in the serum of patients after surgery compared with
that in serum from patients before surgery. Furthermore,miR-210
expression was also higher in patients whose cancer metastasized
to the lymph nodes. These results suggest that circulating miR-210
can be used to predict and perhaps monitor responses to therapies
involving the use of trastuzumab. Elevated levels of HIF-1alpha
were also associated with HER-2 over-expression in invasive breast
cancer (Yamamoto et al., 2008). Moreover, the induction of HER-
2 signaling in breast cancer cells increases HIF-1alpha protein
and vascular endothelial growth factor (VEGF) mRNA expression
(Laughner et al., 2001).
Taken together, these results suggest that miR-210 contributes
to cancer development through immediate effects on the cancer
cells and the modulation of the cancer cell microenvironment, and
when secreted into peripheral blood, circulating miR-210 can be
detected to predict the status of cancer cells in the tumor (Table 1).
EBV miRNAs
Epstein–Barr virus (EBV) encodes miRNAs, which were ﬁrst
reported viral miRNAs in human. A recent study on EBV-infected
normal and neoplastic tissues revealed that distinct EBV miRNA
expression proﬁles are produced in various latency programs,
and EBV miRNAs play key roles in maintaining EBV persistence
through the inhibition of apoptosis and the suppression of the
host immune response (Forte and Luftig, 2011).
Previously, Pegtel et al. (2010) observed that functional EBV
miRNAs, secreted from EBV-infected cells, are transferred to
uninfected recipient cells. These authors showed the miRNA-
mediated repression of conﬁrmed EBV target genes, including
CXCL11. Importantly, in a co-culturing system, containing
EBV-transformed lymphoblastic B cells (donor cells) and pri-
mary immature monocyte-derived dendritic cells (recipient cells),
approximately 2 × 103 copies of EBV-miRNA BART1-5p were
detected in a subset of the recipient cells after 24 h, and this
level increased fourfold (nearly 8 × 103 copies) after an addi-
tional 24 h of co-culture. Moreover, these authors conﬁrmed that
the expression of CXCL11 in recipient cells was down-regulated
within 24 h co-culture, suggesting that the transfer of 2 × 103
copies of EBV-miRNA is sufﬁcient to suppressmiRNA-target genes
in recipient cells. Surprisingly, EBV miRNAs were present in both
B cell and non-B cell fractions in peripheral blood mononuclear
cells obtained from patients with an increased EBV load, although
EBVDNAwas restricted to the circulating B cell population. These
observations indicated that viral miRNAs are functional in non-
infected cells after the transfer of virus miRNAs from infected cells
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Table 1 |The miR-210 studies in the cells and in the extracellular space.
Location Phenotype Origin of miR-210 expression Reference
Intracellular Anti-apoptosis in erythroid cells Erythroid cells Kosaka et al. (2008)
Intracellular Regulate iron homeostasis by targeting ISCU andTfR1 Breast cancer cells Yoshioka et al. (2012)
Intracellular Regulate response to hypoxia by suppressing Ephrin-A3 Endothelial cells Fasanaro et al. (2008)
Intracellular Regulating the hypoxic response of tumor cells and
tumor growth
Renal cancer cells Huang et al. (2009)
Intracellular Promote genetic instability via suppression of RAD52 Cervical carcinoma cells and breast
cancer cells
Crosby et al. (2009)
Extracellular
(endothelial cells)
Promote metastasis via the induction of angiogenesis
through EVs delivery
Metastatic breast cancer cells Kosaka et al. (2013)
Extracellular (blood) High expression in serum from patients who have
trastuzumab-resistance cancer
Drug resistance breast cancer cells Jung et al. (2012)
Extracellular (blood) High expression in CTC-positive patient Breast cancer cells Huang et al. (2009)
EVs, extracellular vesicles; ISCU, iron–sulfur cluster scaffold; TfR1, transferrin receptor 1; CTCs, circulating tumor cells; EPO, erythropoietin.
to non-infected cells through EVs. As shown above, this study
provided the quantitative information on the level of extracellular
miRNAs, which is essential for research on exosomal miRNA-
mediated cell–cell communication. Information, such as the level
of exosomal miRNAs required to suppress target molecules in
recipient cells, might improve the quality of research on exosomal
miRNAs in cell-cell communications.
Nasopharyngeal carcinoma (NPC) is a human epithelial malig-
nancy associated with EBV, and EBV miRNAs are abundantly
found in NPC tumors (Lo et al., 2012). Interestingly, viral miR-
NAs are secreted into the extracellular space from NPC cells
with secreted EVs (Gourzones et al., 2010). In addition, these
miRNAs are not only detected in plasma samples from NPC
xenografted nude mice, but also in plasma samples from NPC
patients. Moreover, EBV miRNAs were signiﬁcantly up-regulated
in tumor tissues compared with non-tumor biopsies, and the dis-
tinct presence of EBV miRNAs in the serum of NPC patients has
been positively correlated with the cellular copy numbers of EBV
miRNAs (Wong et al., 2012). Taken together, these results indi-
cated that the viralmiRNAs secreted fromNPC cells, are contained
inside EVs, resulting in the high stability for diffusion from the
tumor site to the peripheral blood.
Interestingly, non-infected cells harbor miRNAs from viruses,
and this fact might be an important aspect to reconsider infec-
tious diseases. In the case of NPC, several studies have shown
the contribution of EBV miRNAs to cancer development (Lo
et al., 2012), and circulating miRNAs might be useful for the
evaluation of patient status (Gourzones et al., 2010; Wong et al.,
2012). Considering the delivery of EBV miRNAs through EVs,
it is important to characterize the roles of EBV miRNAs in
“non-infected cells” during the development of NPC. Moreover,
miRNAs have been identiﬁed in numerous virus types, such as
herpes B virus, human cytomegalovirus, herpes simplex virus,
and Kaposi’s sarcoma-associated herpes virus, among others.
Thus, it would be important to examine the roles for these viral
miRNAs in non-infected cells. This information might broaden
the current understanding of infectious diseases caused by virus
miRNAs.
miR-21
miR-21 is a well-characterized miRNA that contributes to the
development of cancer (Schetter et al., 2008; Medina et al., 2010),
and the target genes for miR-21 have been identiﬁed as well-
known tumor suppressor genes, such as PTEN (Meng et al., 2007)
and PDCD4 (Asangani et al., 2008). Thus, it is natural to exam-
ine the expression of circulating miR-21 in the serum of cancer
patients for diagnosis. Indeed, several reports have shown the
increased expression of circulating miR-21 in the serum of cancer
patients, including diffuse large B cell lymphoma (DLBCL; Lawrie
et al., 2008), osteosarcoma (Ouyang et al., 2013), colorectal cancer
(Kanaan et al., 2012), hepatocellular carcinoma (HCC; Zhou et al.,
2011), gastric cancer (Li et al., 2012), head and neck squamous
cell carcinoma (Hsu et al., 2012), esophageal squamous cell car-
cinoma (Komatsu et al., 2012), prostate cancer (Yaman Agaoglu
et al., 2011), and glioblastoma (Skog et al., 2008).
Skog et al. (2008) previously reported that glioblastoma tumor
cells release EVs containing mRNA, miRNA, and angiogenic pro-
teins, and these EVs are taken up by normal host cells, such as brain
microvascular endothelial cells. These authors also showed that
miR-21 levels are elevated in serumEVs fromglioblastomapatients
compared with controls. Circulating miR-21 has been reported in
the serum/plasmaobtained fromvarious cancer patients, although
the contribution of miRNAs to cancer development through EVs
has not been discerned. miR-21 acts as an oncogenic miRNA in
various cancer cells and also regulates various phenotypes in the
cancer cellmicroenvironment. Indeed,miR-21 is not only involved
in cancer development but also participates in homeostasis (Niu
et al., 2011); thus, understanding the contribution of miR-21 to the
cellular microenvironment will increase the global understanding
of animal development.
miR-21, associated with RNA-binding proteins, has also been
detected in the culture supernatant from breast cancer cell
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lines (Turchinovich et al., 2011) and serum from healthy donors
(Arroyo et al., 2011), and the abundance of miR-21 in the extracel-
lular spacehas been recognized as shownabove. Thus, determining
the biological signiﬁcance for miR-21 binding to Ago2 might
provide a better understanding of miRNA-associated cell–cell
communication in cancer development.
miR-126
One of the earliest studies to show the transfer of miRNAs between
the cellswas revealed by the study of apoptotic bodies. In this study,
the authors found that endothelial cell-derived apoptotic bodies
contained miR-126 and these apoptotic bodies convey paracrine
alarm signals to recipient vascular cells during atherosclerosis
(Zernecke et al., 2009). In addition, another study also showed
that secretory miR-126 was precipitated in the angiogenesis. The
EVs from CD34+ peripheral blood mononuclear cells exhibited
proangiogenic properties via the transfer of miR-126 (Mocharla
et al., 2013). Cantaluppi et al. (2012a) reported that EVs released
from endothelial progenitor cells (EPCs) enhanced islet endothe-
lial cell proliferation, migration, anti-apoptosis, and organization
in vessel-like structures. They also found that EVs from EPCs
contained the miR-126 and miR-296 and that these miRNAs con-
tributed to the angiogenesis properties, suggesting that EVs from
EPCs activate an angiogenic program in islet endothelium (Can-
taluppi et al., 2012a). They also reported that miR-126 in EVs from
EPCs contributed to the prevention of the ischemic acute injury in
kidney by enhanced tubular cell proliferation, reduced apoptosis,
and leukocyte inﬁltration (Cantaluppi et al., 2012b). In addition,
EPC-derived EVs were able to induce neoangiogenesis and to
enhance recovery in a hindlimb ischemia (Ranghino et al., 2012).
Although circulating miR-126 was enriched in systemic lupus
erythematosus (Wang et al., 2012a), expression of circulating miR-
126 was decreased in the breast cancer (Wang et al., 2010) and
malignant mesothelioma (Tomasetti et al., 2012). Whereas there
are only a few reports regarding the circulating miR-126, secretory
miR-126 from cells has a great activity of endothelial cells activa-
tions as shown in above. Therefore, it is tempting to investigate the
potential of miR-126 as biomarker in diseases which were caused
by the abnormal angiogenesis.
miR-451
Kogure et al. (2011) showed a subset highly enriched miRNAs
within EVs from HCC cells and identiﬁed a target of these miR-
NAs, transforming growth factor β activated kinase-1. Indeed, loss
of this pathway resulted in the enhancement of transformed cell
growth in recipient cells. One of the miRNAs that they identi-
ﬁed in this study, miR-451, was found in the serum from patient
with liver disease. Murakami et al. (2012) investigated the disease
parameters in patients with chronic hepatitis C (CHC) by focus-
ing onmiRNAs isolated fromEV-enriched fraction in serum. They
successfully classiﬁedCHCand normal liver with 96.59% accuracy
using the expression patterns of nine miRNAs including miR-451
(Murakami et al., 2012).
miR-223
Ismail et al. (2013) found that EVs from macrophage contained
miR-223, and that this miR-223 was transported to target cells,
including monocytes, endothelial cells, epithelial cells, and ﬁbrob-
lasts, and was functionally active. Macrophages are found in all
tissues and they play roles in development, homeostasis, tis-
sue repair, and immunity, and thus are therapeutic targets in
many human diseases (Wynn et al., 2013). Indeed, an increased
level of circulating miR-223 was found in serum/plasma from
patients with gastric cancer (Li et al., 2012), non-small cell lung
carcinoma (Sanﬁorenzo et al., 2013), hepatitis B virus-related
HCC (Zhou et al., 2011), NPC (Zeng et al., 2012), hypertension-
induced heart failure (Dickinson et al., 2013), systemic lupus
erythematosus, rheumatoid arthritis (Wang et al., 2012a), sep-
sis (Wang et al., 2012b), ischemic injury (Yu et al., 2009), and
osteoarthritis (Okuhara et al., 2012). To date, origins of this
circulating miR-223 have not been investigated yet; however,
from the reports shown above, macrophage is probable candi-
date of origin for circulating miR-223. Interestingly, miR-223 is
found not only in EVs but also in HDL (Vickers et al., 2011). In
addition, miR-223 concentration in HDL was increased 3,780-
fold with familial hypercholesterolemia when compared with
controls. The HDL is involved in the transport of cholesterol
from lipid-enriched macrophages of atherosclerotic arteries to
the liver. Recently, Wagner et al. (2013) reported that miR-223
was detected at concentrations >10,000 copies/μg in HDL from
healthy subjects. However, HDL-bound miR-223 contributed to
only 8% of the total circulating miRNAs. In addition, a sig-
niﬁcant uptake of HDL-bound miRNAs into endothelial cells,
smooth muscle cells, or peripheral blood mononuclear cells was
not observed, suggesting that the lipoprotein-associated miR-
223 does not regulate the function of the studied cells in vitro.
Knowing the function of secretory miR-223 in macrophage home-
ostasis in vivo might lead to the development of not only the
disease biomarker, but also the novel therapy against atheroscle-
rosis.
miR-150
Zhang et al. (2010) demonstrated that miR-150 from monocytic
cells were delivered into endothelial cell, and this miR-150 reduced
its target gene, c-Myb, expression in endothelial cells, resulting in
the enhancement of cell migration in endothelial cell both in vitro
and in vivo. They also found that monocyte-secreted miR-150
promoted angiogenesis in vivo using tumor-implanted mice and
ob/ob mice as models (Li et al., 2013). Intriguingly, the expres-
sion of miR-150 was higher in EVs isolated from the plasma of
patients with atherosclerosis, and these EVs promoted endothelial
cell migration compared to EVs from healthy donors (Zhang et al.,
2010). A high level of circulating miR-150 was reported in sev-
eral diseases including idiopathic childhood nephrotic syndrome
(Luo et al., 2013), acute myeloid leukemia (Fayyad-Kazan et al.,
2013), and so on. On the contrary, miR-150 serum concentra-
tions upon admission were closely associated with intensive care
unit (ICU) survival as well as long-term survival, and low miR-
150 levels indicated an unfavorable prognosis (Roderburg et al.,
2013).
SUMMARY AND PERSPECTIVES
In this review, we presented the results obtained from research
on miRNAs to provide a better understanding of the relationship
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between secreted miRNAs which contribute to cell–cell commu-
nication in cancer development, and circulating miRNAs which
are used as disease biomarkers.
Recently, a novel concept for biomarkers, called“liquid biopsy,”
has been proposed (Forshew et al., 2012; Murtaza et al., 2013).
Liquid biopsy would be useful for numerous diagnostic appli-
cations and avoid the need for tumor tissue biopsies. Current
studies have shown that genomic alterations in solid cancer can
be characterized through the massively parallel sequencing of
circulating cell-free tumor DNA released from cancer cells into
the plasma (Forshew et al., 2012; Murtaza et al., 2013). This sug-
gests that circulating miRNAs are also good candidates for liquid
biopsy, as the quantities and sequences of miRNAs convey infor-
mation for diagnosis. Particularly, circulating miRNAs, which
have been previously shown to function in cell–cell communica-
tion, might be good candidates for this application. Therefore, we
emphasize that it is important to investigate the function of secre-
tory miRNAs in cell–cell communication, and in parallel explore
the usefulness of these molecules as biomarkers using animal
models.
Much of the current research on circulating miRNAs for dis-
ease biomarkers does not describe the types of circulatingmiRNAs,
such as EVs, microvesicles, HDL/LDLs, or RNA-binding proteins
that are present in human body ﬂuids. As previously discussed,
focusing on a speciﬁc type of circulating miRNAs, such as exoso-
mal miRNAs or miRNAs bound to RNA-binding proteins, might
be useful as disease biomarkers compared with analyzing the
total miRNA in human body ﬂuids. Indeed, EV-enriched frac-
tions isolated from patients with liver disease were useful for the
determination of disease progression compared with the proﬁles
obtained using total miRNA present in serum samples (Murakami
et al., 2012). Therefore, it is essential that future studies concerning
circulating miRNAs for diagnostic purposes should focus on the
type of circulating miRNAs present in body ﬂuids.
One of the crucial issues in research on cell–cell communica-
tion by secretory miRNAs is whether the secretory miRNAs which
researcher identiﬁed are really physiologically functional enough
or not. This issue might be revealed by showing the quantitative
data of secretory miRNAs in more detail, such as the number of
EVs, the number of miRNAs, and the number of cells. In addi-
tion, in the case of functional demonstration of secretorymiRNAs,
over-expression or knock-down of secretory miRNAs was per-
formed; however, contamination of exogenous miRNAs, such as
synthetic miRNAs, should be cared since the amount of those
exogenous miRNAs are usually introduced in excess. The study on
extracellular miRNAs has just begun. Thus, the researcher work-
ing on the EVs needs to take care of the physiological amount of
those molecules in their research ﬁeld.
Another crucial issue of extracellular miRNAs that how these
miRNAs are secreted from cells and how these miRNAs work in
the cells has not been answered yet, although recent reports proved
the physiological and pathological importance of secretory miR-
NAs not only in vitro but also in vivo. We previously found that
secretion of miRNAs from cells was regulated by neutral sph-
ingomyelinase 2, which is known as a rate-limiting enzyme of
ceramide biosynthesis and triggers secretion of EVs (Kosaka et al.,
2010b). Although the molecules that are essential for EVs secre-
tionhas been reported, their contribution tomiRNAs secretionhas
not been tested yet. One of the most important points for under-
standing of miRNAs secretion is the identiﬁcation of a protein that
binds to miRNAs in EVs. miRNAs are strongly bound to the Ago2
protein, which is a main component of the RNA-induced silencing
complex (RISC), in the cells (Kim et al., 2009), but this molecule
is not found in EVs (Gibbings et al., 2009). Meanwhile, knock-
down of GW182, another main component of the RISC, reduced
miRNA secretion via EVs. Interestingly, however, GW182 was not
detected in the EVs from HEK293 (Yao et al., 2012). In contrast
to the above report, GW182 can be found in EVs from mono-
cyte, HeLa cells and ex vivo-derived dendritic cells (Gibbings et al.,
2009). These paradoxical observations indicate that further exper-
iments are required to elucidate whether there is a role for GW182
in miRNA secretion. Identiﬁcation of proteins that are respon-
sible for the transport of miRNAs from inner cells to inner EVs
might reveal many of mysteries of secretory miRNAs in cell–cell
communications.
CirculatingRNAhas beenpreviously considered as“trash”from
cells; however, we propose that this “trash” serves as a commu-
nication tool and should therefore be referred to as “treasure.”
Analyzing circulating miRNAs in human body ﬂuids might pro-
vide a method for “listening” to the communication between cells,
leading to the development of disease treatments based on the
mechanisms of secreted miRNAs in cancer development.
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